TNFRSF19 gene – Talk Bio

Pfizer’s Bourla is ‘cautiously optimistic’ on tariffs, says M&A is on the table

1 month ago talkbio0Tagged Bourla, M&A, Pfizer, Policy, tariffs, TNFRSF19 gene, United States

Bourla, M&A, Pfizer, United States, TNFRSF19 gene, Policy, tariffs

Pfizer CEO Bourla suggests pharma tariffs will focus on US adversaries, not allies

1 month ago talkbio0Tagged Administration occupational activities, Albert, Bourla, chain concerns, Evaluation, Investments, Manufacturing, National Security, pharmaceutical tariffs, Policy, Sectioning technique, TNFRSF19 gene, Transplant Registry Unified Management Program

Pharmaceutical tariffs, Section 232 investigation, Albert Bourla, national security, trade policy, manufacturing investments, Trump administration, supply chain concerns

U.S. Biotechs Reveal Tariff Exposure as Trade Inquiry Signals Imminent Pharmaceutical Tariffs

2 months ago talkbio0Tagged Evaluation, global supply chain, Impact food supplement, Import, Manufacturing, pharmaceutical ingredients, pharmaceutical tariffs, Policy, regulatory, reshoring, Sectioning technique, supply chain exposure, TNFRSF19 gene, United States

U.S. biotech, pharmaceutical tariffs, Section 232 investigation, supply chain exposure, trade policy, import costs, reshoring manufacturing, drug pricing, global supply chain, pharmaceutical ingredients, regulatory impact

Trump Announces Imminent Major Tariffs on Pharmaceuticals: Implications for Global Markets and U.S. Manufacturing

2 months ago talkbio0Tagged drug price, Impact food supplement, Pharma import taxes, pharmaceutical manufacturing, Pharmaceutical stocks, pharmaceutical tariffs, Policy, Relations, TNFRSF19 gene, Transplant Registry Unified Management Program, U.S.-China, United States

Trump pharmaceutical tariffs, U.S. pharmaceutical manufacturing, Pharma import taxes, Drug price impact, Trade policy 2025, U.S.-China trade relations, Pharmaceutical stocks

Trump’s Looming Pharmaceutical Tariffs: Uncertainty and Potential Impact

2 months ago talkbio0Tagged Manufacturing, pharmaceutical tariffs, Policy, Prices, TNFRSF19 gene, Transplant Registry Unified Management Program

Trump, pharmaceutical tariffs, trade policy, drug prices, manufacturing, supply chain

Indian Biomanufacturing Alliance: Boosting National Capabilities

3 months ago talkbio0Tagged Asian Indian, biomanufacturing, Collaboration, drugmakers, national sector growth, TNFRSF19 gene

Indian drugmakers, biomanufacturing, trade group, collaboration, national sector growth

Pfizer’s European Manufacturing Vulnerable to Potential US Tariffs, CEO Warns

4 months ago talkbio0Tagged Albert, Bourla, chain disruption, Drug Industry, European (ethnic group), Manufacturing, Pfizer, Tension, TNFRSF19 gene, U.S.

Pfizer, Albert Bourla, European manufacturing, US tariffs, pharmaceutical industry, trade tensions, supply chain disruption

Illumina’s Double-Edged Sword: Navigating US-China Trade Tensions

4 months ago talkbio0Tagged BIOSECURE, China, DNA Sequence, Entity, Illumina, Industry, Tension, TNFRSF19 gene, unreliable

Illumina, China, tariffs, trade tensions, DNA sequencing, unreliable entity list, biotech industry, BIOSECURE Act

Pharmaceutical Industry Warns of Drug Shortages and Price Hikes Due to Trump’s New Tariffs

4 months ago talkbio0Tagged Active, APIs, chain disruption, Drug Industry, Drug shortages, Groups, Increased, Prices, TNFRSF19 gene, Trump tariffs

Trump tariffs, drug shortages, price increases, pharmaceutical industry, trade groups, supply chain disruption, generic drugs, active pharmaceutical ingredients (APIs)

Trump Imposes New Tariffs on Canada, Mexico, and China; Medical Industry Seeks Exemptions

4 months ago talkbio0Tagged Canada, China, fentanyl crisis, illegal immigration, medical technology exemptions, Mexico, National Security, Policy, TNFRSF19 gene, Trump tariffs

Trump tariffs, Canada, Mexico, China, medical technology exemptions, trade policy, national security, fentanyl crisis, illegal immigration